• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
• /
• pp.115.1-115.1
• /
• 2003

Cadmium, a human carcinogen, can induce apoptosis in various cell lines. Despite extensive research, the mechanisms of cadmium-induced apoptosis are poorly understood, and its toxicity and estrogenic potential in human are not clear. This study was performed to investigate the apoptotic activities of cadmium on two human breast cancer cell lines: MCF-7 cells, an estrogen receptor (ER) positive cell line, and MDA-MB-231 cells, an ER negative cell line. Both cells were treated with $CdCl_2$ 100$\mu$M for 12hrs, and the spoptosis was determined by DNA fragmentation, DAPI staining, and expression of caspase-9. (omitted)

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권23호
• /
• pp.10263-10266
• /
• 2015

Background: The risk of febrile neutropaenia (FN) and treatment related death (TRD) with first line palliative chemotherapy for de novo metastatic breast cancer (MBC) remains unknown outside of a clinical trial setting despite its widespread usage. This study aimed to determine rates in a large cohort of patients treated in the University of Malaya Medical Centre (UMMC). Materials and Methods: Patients who were treated with first line palliative chemotherapy for de novo MBC from 2002-2011 in UMMC were identified from the UMMC Breast Cancer Registry. Information collected included patient demographics, histopathological features, treatment received, including the different chemotherapy regimens, and presence of FN and TRD. FN was defined as an oral temperature > $38.5^{\circ}C$ or two consecutive readings of > $38.0^{\circ}C$ for 2 hours and an absolute neutrophil count < $0.5{\times}10^9/L$, or expected to fall below $0.5{\times}10^9/L$ (de Naurois et al, 2010). TRD was defined as death occurring during or within 30 days of the last chemotherapy treatment, as a consequence of the chemotherapy treatment. Statistical analysis was performed using the SPSS version 18.0 software. Survival probabilities were estimated using the Kaplan-Meier method and differences in survival compared using log-rank test. Results: Between $1^{st}$ January 2002 and $31^{st}$ December 2011, 424 patients with MBC were treated in UMMC. A total of 186 out of 221 patients with de novo MBC who received first line palliative chemotherapy were analyzed. The mean age of patients in this study was 49.5 years (range 24 to 74 years). Biologically, ER status was negative in 54.4% of patients and Her-2 status was positive in 31.1%. A 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy regimen was chosen for 86.6% of the cases. Most patients had multiple metastatic sites (58.6%). The main result of this study showed a FN rate of 5.9% and TRD rate of 3.2%. The median survival (MS) for the entire cohort was 19 months. For those with multiple metastatic sites, liver only, lung only, bone only and brain only metastatic sites, the MS was 18, 24, 19, 24 and 8 months respectively (p-value= 0.319). Conclusions: In conclusion, we surmise that FEC is a safe regimen with acceptable FN and TRD rates for de novo MBC.

• Journal of Ginseng Research
• /
• 제43권4호
• /
• pp.527-538
• /
• 2019

Background: Ginsenoside Rg1 was shown to exert ligand-independent activation of estrogen receptor (ER) via mitogen-activated protein kinase-mediated pathway. Our study aimed to delineate the mechanisms by which Rg1 activates the rapid ER signaling pathways. Methods: ER-positive human breast cancer MCF-7 cells and ER-negative human embryonic kidney HEK293 cells were treated with Rg1 ($10^{-12}M$, $10^{-8}M$), $17{\beta}$-estradiol ($10^{-8}M$), or vehicle. Immunoprecipitation was conducted to investigate the interactions between signaling protein and ER in MCF-7 cells. To determine the roles of these signaling proteins in the actions of Rg1, small interfering RNA or their inhibitors were applied. Results: Rg1 rapidly induced $ER{\alpha}$ translocation to plasma membrane via caveolin-1 and the formation of signaling complex involving linker protein (Shc), insulin-like growth factor-I receptor, modulator of nongenomic activity of ER (MNAR), $ER{\alpha}$, and cellular nonreceptor tyrosine kinase (c-Src) in MCF-7 cells. The induction of extracellular signal-regulated protein kinase and mitogen-activated protein kinase kinase (MEK) phosphorylation in MCF-7 cells by Rg1 was suppressed by cotreatment with small interfering RNA against these signaling proteins. The stimulatory effects of Rg1 on MEK phosphorylation in these cells were suppressed by both PP2 (Src kinase inhibitor) and AG1478 [epidermal growth factor receptor (EGFR) inhibitor]. In addition, Rg1-induced estrogenic activities, EGFR and MEK phosphorylation in MCF-7 cells were abolished by cotreatment with G15 (G protein-coupled estrogen receptor-1 antagonist). The increase in intracellular cyclic AMP accumulation, but not Ca mobilization, in MCF-7 cells by Rg1 could be abolished by G15. Conclusion: Ginsenoside Rg1 exerted estrogenic actions by rapidly inducing the formation of ER containing signalosome in MCF-7 cells. Additionally, Rg1 could activate EGFR and c-Src ER-independently and exert estrogenic effects via rapid activation of membrane-associated ER and G protein-coupled estrogen receptor.

• 생명과학회지
• /
• 제26권12호
• /
• pp.1383-1391
• /
• 2016

타목시펜과 같은 항에스트로젠은 ER 양성의 초기 유방암 환자에게 사용되고 있다. 그러나 대부분의 환자에서 이 항에스트로젠에 대한 내성 발현은 불가피하게 발생한다. BCAR3 유전자는 사람의 에스트로젠 의존성 유방암에서 tamoxifen 내성유도를 야기하는 단백질로 발견되었다. 우리들은 이전에 이 BCAR3 유전자가 세포주기 진행과 EGF와 인슐린에 의한 DNA 합성 신호전달경로를 조절한다고 보고하였다. 본 연구에서는, 비종양성 정상적인 인간유방상피세포인 MCF-12A세포에서 c-Jun 전자의 조절에 대한 BCAR3유전자의 기능적인 역할을 조사하였다. BCAR3의 일시적인 발현 또는 지속적인 발현이 c-Jun mRNA와 단백질의 발현을 증가하는 것을 발견하였다. 또한 BCAR3 발현 유전자의 미세주사에 의해 세포 증식이 증가하였다. 이 c-Jun의 발현 증가는 promoter의 활성화를 통해 일어난다. 또한 BCAR3에 의한 c-Jun 발현 유도가 억제성 Ras, Rac, Rho에 의해 억제되었다. 다음으로 EGF 성장인자에 의한 c-Jun 발현 유도에 대한 BCAR3의 영향을 단일 세포 미세주사법에 의해 조사하였다. BCAR3 항체, BCAR3의 siRNA와 같은 BCAR3의 기능을 억제할 수 있는 물질들을 세포로 미세주사하면 EGF에 의한 c-Jun의 발현을 억제하였지만, IGF-1 성장인자에 의한 c-Jun 발현은 억제하지 않았다. 이러한 결과들로부터 BCAR3는 c-Jun 단백질 발현 유도와 세포 증식에 중요한 역할을 하며, 여기에는 Ras, Rac, Rho와 같은 GTPase들이 필요하다는 것을 발견하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권11호
• /
• pp.5339-5343
• /
• 2012

The induction of apoptosis in target cells is a key mechanism for most anti-tumor therapies. Bufalin is a cardiotonic steroid that has the potential to induce differentiation and apoptosis of tumor cells. Research on bufalin has so far mainly involved leukemia, prostate cancer, gastric cancer and liver cancer, and has been confined to in vitro studies. The bufadienolides bufalin and cinobufagin have been shown to induce apoptosis in a wide spectrum of cancer cell. The present article reviews the anticancer effects of bufalin. It induces apoptosis of lung cancer cells via the PI3K/Akt pathway and also suppressed the proliferation of human non-small cell lung cancer A549 cell line in a time and dose dependent manner. Bufalin, bufotalin and gamabufotalin, key bufadienolides, significantly sensitize human breast cancer cells with differing ER-alpha status to apoptosis induction by the TNF-related apoptosis-inducing ligand (TRAIL). In addition, bufadienolides induce prostate cancer cell apoptosis more significantly than that in breast epithelial cell lines. Similar effects have been observed with hepatocellular carcinoma (HCC) but the detailed molecular mechanisms of inducing apoptosis in this case are still unclear. Bufalin exerts profound effects on leukemia therapy in vitro. Results of multiple studies indicate that bufalin has marked anti-tumor activities through its ability to induce apoptosis. Large-scale randomized, double-blind, placebo or positive drug parallel controlled studies are now required to confirm the efficacy and apoptosis-inducing potential of bufalin in various cancers in the cliniucal setting.

• 생명과학회지
• /
• 제20권9호
• /
• pp.1324-1331
• /
• 2010

Mifepristone (MIF)와 Tamoxifen (TAM)은 각각 전립선암과 유방암치료제로 오랫동안 사용되고 있다. MIF는 안드로겐수용체(AR) 양성인 세포와 음성이 세포 모두에서 세포사멸을 유도하며, TAM 은, 리간드-수용체작용 기작의 다양한 특성에 의하여 에스트로겐(ER) 양성인 세포뿐 만 아니라 다른 종류의 암세포에서도 세포사멸을 유도하는 것으로 알려져 있다. 본 연구에서는 AR 음성인 DU-145 전립선암세포에 있어서, MIF와 TAM의 세포독성이 세포 내 칼슘농도 변화에 기인된 세포사멸기작에 의한 것임을 보여준다. MIF와 TAM을 처리시 세포성장은 농도와 시간의존적으로 감소하였으며, confocal laser scanning microscopy (CLSM)과 fluorescence-activated cell sorting (FASC)로 세포를 분석한 결과 각각 MIF와 TAM을 2일간 처리한 세포에서 세포사멸이 진행되는 것을 관찰하였다. 세포독성효과를 비교했을 경우, TAM이 MIF 보다 강하게 작용하였다. MIF와 TAM을 처리한 세포 내 칼슘변화 측정 시, 칼슘농도 또한 처리 약물의 농도와 시간 의존적으로 증가하였다. 1.5 mM 칼슘배지와 칼슘제거된 배지에서의 실험결과를 비교한 바, 세포 내 칼슘증가는 외부로부터의 유입에 의한 것으로 생각된다. 세포독성효과와 마찬가지로 칼슘증대 효과 역시 TAM에서 뚜렷하게 나타났다. 수용체 매개 세포사멸기작의 초기에 관여하는 procaspase-8은 MIF 처리 시 뚜렷이 활성화 되었으나, TAM의 경우 활성화가 MIF의 경우에 비해 강하지 못하였다. 그러나, 세포사멸의 중추적인 역할을 하는 caspase-3은 TAM 을 처리한 세포에 있어서 활성 정도가 훨씬 높았다. 세포사멸과정의 중요한 조절 단백질인 Bcl-2 그룹단백질의 발현을 조사해 본 결과, 세포사멸 억제단백질인 Bcl-2의 발현은 MIF, TAM 처리 시 동일하게 감소한 반면, 촉진단백질인 Bax의 발현은 2-3배 가량 증대되었다. 이상의 결과로 보아 MIF와 TAM은 세포 내 칼슘조절을 통하여 세포사멸을 유도하나, 세포사멸의 초기단계는 MIF와 TAM이 서로 다른 경로를 경유할 가능성이 있는 것으로 생각된다.